XenoPort Issues Statement
October 15 2013 - 8:36PM
Business Wire
XenoPort, Inc. (NASDAQ: XNPT) today issued the following
statement:
“The XenoPort Board of Directors has received the letter sent
today from the Clinton Group. The XenoPort Board and management
team appreciate stockholder input regarding the company, and we
will continue to review all aspects of the company’s business. We
remain focused on enhancing stockholder value and welcome
stockholder input regarding this objective.”
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets, its first approved
product in the United States, and developing a novel fumaric acid
ester product candidate, XP23829, as a potential treatment for
relapsing-remitting multiple sclerosis and/or psoriasis. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed
in Japan by Astellas Pharma Inc. XenoPort's pipeline of product
candidates also includes potential treatments for patients with
spasticity related to spinal cord injury and Parkinson's
disease.
To learn more about XenoPort, please visit the company Website
at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2G
XenoPortJackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2024 to May 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Xenoport, Inc. (NASDAQ): 0 recent articles
More Xenoport, Inc. (MM) News Articles